Rose Geoffrey Beran sold $18K of LUNG

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

Pulmonx Corporation reported Q3 2026 revenue growth in U.S. and international markets, with adjusted EBITDA loss decreasing by nearly 60%. The company maintained FY 2026 revenue guidance of $90M–$92M, citing cost discipline and sales-team productivity.

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

Pulmonx (Nasdaq: LUNG) reported Q2 2026 revenue of $22.8 million, down 5% year over year, with U.S. revenue at $14.2 million (-4%) and international at $8.6 million (-6%). Gross margin rose to 78%. Net loss was $10.1 million, down from $15.2 million. Full-year 2026 revenue guidance is $90 million to $92 million.